Skip to main content

GLP-1 receptor agonists: Cost Comparison

GLP-1 (glucagon-like peptide-1) receptor agonists are injectable medicines used to lower blood sugar in type 2 diabetes; some are also separately approved for weight management. They are among the highest-cost drugs in the Medicare Part D programme.

Across these 3 drugs, average Medicare Part D spending per dosage unit ranges from $306.48 (Ozempic) to $511.63 (Mounjaro) for calendar year 2024. Figures are real CMS open data, in US dollars.

How much do glp-1 receptor agonists cost in the US?

As of calendar year 2024, average Medicare Part D spending per dosage unit for these 3 glp-1 receptor agonists ranged from $306.48 (Ozempic) to $511.63 (Mounjaro), per CMS open data. These are Medicare program spending figures per billing unit — not pharmacy cash prices, and not medical advice.

Source:CMS Medicare Part D Spending by Drug·as of calendar year 2024updated yearly (last: )
Not medical advice — and not a like-for-like price. Each figure is average Medicare Part D program spending per dosage unit, taken unchanged from a public US government dataset. A “dosage unit” differs between drugs (one tablet, one mL, one pen, etc.), so a higher per-unit figure does not always mean a higher monthly cost. These are not pharmacy cash prices, not per-prescription costs, and not price quotes. Always consult a licensed pharmacist or clinician about type 2 diabetes (and, separately, weight management).
GLP-1 receptor agonists — CMS Medicare Part D average spending per dosage unit, calendar year 2024 (CMS, public domain)
DrugGeneric (active ingredient)Avg Part D spending / dosage unit2024 Part D claims
OzempicSemaglutide$306.4810,417,182
MounjaroTirzepatide$511.635,105,397
TrulicityDulaglutide$467.754,305,141

Figures are CMS’s own published Medicare Part D spending values (field Avg_Spnd_Per_Dsg_Unt_Wghtd_2024), reported unchanged. The most-prescribed drug in this group in 2024 was Ozempic (10.4 million claims). View the full dataset on CMS data.cms.gov.

Each drug in detail

Look up any Part D drug

Search the highest-volume Medicare Part D drugs by brand or generic name to see real average spending per dosage unit and 2024 claim volume.

Ozempic

Semaglutide
Avg Medicare Part D spending
$306.48 / dosage unit
calendar year 2024
2024 Part D claims
10,417,182
how common it is

This is average Medicare Part D program spending per dosage unit, not a pharmacy cash price or a per-prescription cost. Information only — not medical advice and not a price quote.

Compare other drug classes

Frequently asked questions

Which glp-1 receptor agonists are compared here?
This page compares 3 glp-1 receptor agonists from the CMS Medicare Part D dataset (calendar year 2024): Ozempic, Mounjaro, Trulicity. Each is shown with its real average Medicare Part D spending per dosage unit in US dollars.
What is the cheapest glp-1 receptor agonist by Medicare spending per unit?
Among these drugs, Ozempic had the lowest average Medicare Part D spending per dosage unit at $306.48 (calendar year 2024), and Mounjaro the highest at $511.63. This is program spending per billing unit, not a retail price, and dosage units differ between drugs.
Is this the price I would pay for glp-1 receptor agonists?
No. These figures are average Medicare Part D program spending per dosage unit from CMS open data, not a pharmacy cash price or per-prescription cost. What you pay depends on your pharmacy, insurance, manufacturer, dose and region. This is information only, not medical advice.
Can a GeraClinic clinician help with type 2 diabetes (and, separately, weight management)?
A GeraClinic clinician can review your medication for type 2 diabetes (and, separately, weight management), explain the options, and issue or renew a prescription online where clinically appropriate. GeraClinic only lists independently verified, licensed clinicians.

Need help with type 2 diabetes (and, separately, weight management)?

A GeraClinic clinician can review your medication, explain the options, and issue or renew a prescription online where clinically appropriate — without travelling to a clinic.

Contains public sector information published by U.S. Centers for Medicare & Medicaid Services (CMS) and licensed under the U.S. Government Works / Public Domain. Source: CMS Medicare Part D Spending by Drug (calendar year 2024, published 2026-06-25).

Informational/educational only — not a substitute for professional medical advice; a clinician interprets results.